TEVA Q3 2025 Earnings Call Summary

Revenue: $4.5 billion, up 3% year-over-year (11th consecutive quarter of growth).
Adjusted EBITDA: Increased by 6%.
Non-GAAP EPS: $0.78, a 14% increase year-over-year.
Free Cash Flow: $515 million, down from $922 million in Q3 2024, attributed to timing of sales and higher legal settlement payments.
Net Debt to EBITDA: Below 3x for the first time since 2016, with expectations to reach around 2.8x by year-end.

Growth Strategy: Focused on four pillars: driving innovative products (AUSTEDO, UZEDY, AJOVY), enhancing innovation, stabilizing generics, and business transformation.
Innovative Products:
- AUSTEDO: Revenue of $618 million (up 38% YoY); 2027 revenue target confirmed at $2.5 billion.
- UZEDY: Revenue of $43 million (up 24% YoY); peak sales target reiterated at $1.5 billion to $2 billion.
- AJOVY: Revenue of $168 million (up 19% YoY); guidance maintained at $630 million to $640 million.
Generics Business: Grew 2% YoY, with U.S. generics up 7%, but European generics down 5% due to tough comparisons.
Biosimilars: 10 in-line assets with potential for 6 more launches by 2027, projected to add $400 million by that year.
Transformation Program: On track to achieve $700 million in savings by 2027, with approximately half already realized.

2025 Revenue Guidance: Tightened to $16.8 billion to $17 billion, with AUSTEDO's outlook increased by $50 million to $100 million.
Operating Margin: Expected to reach 30% by 2027, with a 27% margin anticipated for 2025.
Free Cash Flow Guidance: Maintained at $1.6 billion to $1.9 billion for 2025.
Long-term Targets: Reiterated 2027 targets, including AUSTEDO exceeding $2.5 billion in revenue.

Generics Market Pressures: European generics faced declines due to tough year-over-year comparisons and loss of market share.
Free Cash Flow Decline: Notable drop from $922 million in Q3 2024 to $515 million in Q3 2025 due to timing and legal costs.
TAPI Divestiture: Initial sale discussions did not result in an agreement, leading to a renewed search for buyers amid changing market conditions.

AUSTEDO Negotiations: Management confirmed that the outcome of the IRA negotiations was in line with expectations, supporting confidence in future revenue targets.
Competitive Pressures: Concerns were raised about potential pricing pressures from competitors, particularly regarding AUSTEDO XR.
Biosimilars Strategy: FDA's proposed guidance on biosimilars was welcomed, aligning with Teva's existing strategy and potentially reducing costs and approval times.
TAPI Asset: Management decided to restart the sales process for TAPI due to its strategic importance and recent market shifts, emphasizing the need for favorable terms.

This summary encapsulates the key aspects of Teva's Q3 2025 earnings call, highlighting both achievements and challenges faced by the company.

TEVA — Teva Pharmaceutical Industries Limited